LY 518674

Drug Profile

LY 518674

Alternative Names: LY 674; LY518674

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Eli Lilly; Ligand Pharmaceuticals
  • Class Antihyperglycaemics; Antihyperlipidaemics
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Lipid metabolism disorders

Most Recent Events

  • 23 Mar 2009 Discontinued - Phase-I for Lipid metabolism disorders in USA (PO)
  • 23 Mar 2009 Discontinued - Phase-II for Atherosclerosis in USA (PO)
  • 11 Apr 2007 Data presented at the 56th Annual Scientific Session of the American College of Cardiology (ACC-2007) have been added to the adverse events and Hyperlipidaemia therapeutic trials sections ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top